Ferrini W, Ambresin A
Jules Gonin Eye Hospital, Medical Retina Unit, University of Lausanne, Switzerland.
Klin Monbl Augenheilkd. 2013 Apr;230(4):423-6. doi: 10.1055/s-0032-1328388. Epub 2013 Apr 29.
To study the efficacy and safety of a new intravitreal implant (sustained release of dexamethasone, Ozurdex®) recently approved in Switzerland for the treatment of macular edema secondary to retinal vein occlusion in a clinical setting.
Prospective non-consecutive study of patients with macular edema secondary to central retinal vein occlusion or branch retinal vein occlusion treated with implant of dexamethasone 0.7 mg. Follow-up visits were performed at day 1, week 1 and monthly thereafter. ETDRS best corrected visual acuity, Goldmann tonometry and macular thickness on SD-OCT were registered. Retreatment was carried out on a pro re nata basis starting from month 3.
Fifteen eyes of 15 patients were included (8 branch retinal vein occlusions, 7 central retinal vein occlusions). 33% of the patients achieved 3 lines or more of vision gain. The central retinal vein occlusion subgroup showed a mean decline in visual acuity at month 3. A reduction of 36% of macular edema was already observed at day 1. All maculae were dry at month 1. The mean time of recurrence of macular edema for both groups was 4.6 months. A similar reduction of macular edema was obtained after a second implantation. An intraocular pressure increase of ≥ 20% was observed after the first implantation in 53% of patients.
Our study showed efficacy and safety of intravitreal dexamethasone implant in the treatment of macular edema due to retinal vein occlusion. Anatomical efficacy was observed at day 1 but seems to have shorter effect than previously published data. No serious side effects were observed.
研究一种新的玻璃体内植入物（地塞米松缓释剂，Ozurdex®）在临床环境中治疗视网膜静脉阻塞继发黄斑水肿的有效性和安全性，该植入物最近在瑞士获得批准。
对接受0.7毫克地塞米松植入治疗的视网膜中央静脉阻塞或视网膜分支静脉阻塞继发黄斑水肿的患者进行前瞻性非连续性研究。在第1天、第1周及之后每月进行随访。记录ETDRS最佳矫正视力、Goldmann眼压测量值和SD-OCT上的黄斑厚度。从第3个月开始根据具体情况进行再次治疗。
纳入15例患者的15只眼（8只视网膜分支静脉阻塞，7只视网膜中央静脉阻塞）。33%的患者视力提高了3行或更多。视网膜中央静脉阻塞亚组在第3个月时视力平均下降。在第1天已观察到黄斑水肿减轻36%。在第1个月时所有黄斑均变干。两组黄斑水肿复发的平均时间为4.6个月。第二次植入后黄斑水肿也有类似程度的减轻。53%的患者在首次植入后眼压升高≥20%。
我们的研究表明玻璃体内地塞米松植入物治疗视网膜静脉阻塞所致黄斑水肿具有有效性和安全性。在第1天观察到解剖学上的疗效，但似乎比先前发表的数据效果持续时间更短。未观察到严重副作用。
